Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
NCT03933904Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Sep 2019
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in idiopathic multicentric Castleman disease (iMCD), sponsored by University of Pennsylvania. Primary endpoint: Percentage of Patients Achieving a Positive Clinical Benefit Response at 12 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT03933904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933904.